Compare Ross Stores, Inc. (ROST) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs TransMedics Group Inc — how do they compare? Ross Stores, Inc. trades at $225.21 (market cap $73.25B), while TransMedics Group Inc trades at $86.4 (market cap $3.06B). The key difference: Ross Stores, Inc. is far larger — about 23.9× TransMedics Group Inc's market cap, and Ross Stores, Inc. pays a 0.78% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ROST | TMDX | |
|---|---|---|
Market Cap | $73.25B | $3.06B |
Sector | Consumer Cyclical | Technology |
52-Week High | $255.23 | $150.42 |
52-Week Low | $144.67 | $61.99 |
Enterprise Value | $73.70B | $3.46B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $229.31, down 0.6% on the day, amid a bearish technical signal but strong fundamental performance. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $2.66 surpassing the $1.95 forecast, and raised its full-year outlook. Revenue reached $21.13B in 2025, with net income of $2.09B and robust profitability metrics, including a 42.63% ROE. Analysts maintain a bullish consensus with a $271.33 price target, though technical indicators show near-term resistance.
The outlook for ROST is positive, driven by strong execution, expanding margins, and resilient consumer demand for value retail. Investment opportunities include continued earnings growth and potential upside to analyst targets. Key risks involve macroeconomic sensitivity, competitive pressures, and any deviation from its traffic growth trajectory. The stock's valuation at a P/E of 27.73 requires sustained performance to justify further gains.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
